XTL Biopharmaceuticals Ltd. (XTLB.TA)
Tel Aviv · ILA · Healthcare · Biotechnology
ILA 1.50 (+0.00%) as of
Key statistics
- Market cap
- 14.74M
- EPS (TTM)
- -0.0000
- Dividend yield
- 0.00%
- 52-week range
- 0.0180 – 2.2000
- Beta
- 0.43
- Profit margin
- 0.00%
- Volume
- 21.00k
About XTL Biopharmaceuticals Ltd.
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. The company's lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Herzliya, Israel.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Herzliya, Israel
- Employees
- 4
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.